No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
151 |
4. Check minimum number of eventsNone |
151 |
5. Include endpointsNone |
151 |
6. Filter based on genotype QC (FinnGen only) |
146 |
Control definitions (FinnGen only)
- Control exclude
- N14_GLOMERULAR
Extra metadata
- Level in the ICD hierarchy
- 4
Similar endpoints
↥List of similar endpoints to
Membranous nephropathy
based on the number of shared cases.
Similar with more cases:
- Chronic nephritic syndrome
- Glomerulonephritis
- Glomerular diseases
- All chronic kidney diseases
- All kidney diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 146 | 60 | 86 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 53.49 | 49.49 | 56.27 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 151
- Matched controls
- 1510
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N03.2
ICD-10 Finland
Chronic nephritic syndrome, diffuse membranous glomerulonephritis
+∞
195.2
142
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
22.8
63.8
53
35
N04.2
ICD-10 Finland
Nephrotic syndrome, diffuse membranous glomerulonephritis
+∞
63.0
56
*
C03CA01
ATC
furosemide; systemic
12.1
49.2
113
298
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
130.8
44.7
46
5
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
531.8
42.3
40
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
278.7
42.2
41
*
H02AB04
ATC
methylprednisolone; systemic
9.2
40.3
69
127
N04.9
ICD-10 Finland
Nephrotic syndrome, unspecified
+∞
39.3
36
*
L04AA06
ATC
mycophenolic acid; systemic
167.7
37.7
38
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
76.9
36.3
40
7
A11CC03
ATC
alfacalcidol; systemic
100.5
35.8
38
5
L04AD01
ATC
ciclosporin; systemic
67.3
35.6
40
8
L04AA01
ATC
[U] ciclosporin
150.5
34.3
35
*
A12AA04
ATC
calcium carbonate; oral
145.0
33.2
34
*
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
32.5
30
*
C09AA02
ATC
enalapril; systemic
6.9
31.4
74
184
N18.8
ICD-10 Finland
Other chronic renal failure
72.4
30.6
34
6
R80
ICD-10 Finland
Isolated proteinuria
129.0
29.9
31
*
127
Kela drug reimbursment
Transplant complication
356.8
29.9
29
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
341.1
28.8
28
*
N18.0
ICD-10 Finland
End-stage renal disease
+∞
28.0
26
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
113.7
26.7
28
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.9
26.5
53
110
N03.9
ICD-10 Finland
Chronic nephritic syndrome, unspecified
+∞
25.8
24
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
+∞
24.7
23
*
N00.2
ICD-10 Finland
Acute nephritic syndrome, Diffuse membranous glomerulonephritis
+∞
23.5
22
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
22.4
21
*
TK800
NOMESCO Finland
Hemodialysis
37.7
22.4
28
9
205
Kela drug reimbursment
Chronic hypertension
5.0
21.7
77
260
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
21.3
20
*
C08CA02
ATC
felodipine; oral
7.0
21.3
38
69
C02AC05
ATC
moxonidine; oral
9.9
20.8
26
31
B03XA02
ATC
darbepoetin alfa; parenteral
42.4
20.6
25
7
ZX120
NOMESCO Finland
Intravenous
6.4
20.4
40
80
5821B
ICD-9 Finland
Chronic glomerulonephritis, With lesion of membranous glomerulonephritis[GLOMERULONEPHRITIS CHRONICA MEMBRANACEA,NEFR SDR]
+∞
20.3
19
*
N03.8
ICD-10 Finland
Chronic nephritic syndrome, other
+∞
19.2
18
*
V03AE01
ATC
polystyrene sulfonate; oral
60.5
18.5
21
*
N03.3
ICD-10 Finland
Chronic nephritic syndrome, diffuse mesangial proliferative glomerulonephritis
+∞
18.1
17
*
C10AA05
ATC
atorvastatin; oral
4.5
17.3
104
499
N18.5
ICD-10 Finland
Chronic kidney disease, stage 5
101.5
17.0
18
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
190.1
16.9
17
*
L04AD02
ATC
tacrolimus; systemic
190.1
16.9
17
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
8.3
16.2
23
32
137
Kela drug reimbursment
Uraemia requiring dialysis
+∞
15.9
15
*
N03.1
ICD-10 Finland
Chronic nephritic syndrome, focal and segmental glomerular lesions
+∞
15.9
15
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
17.8
15.0
23
15
B03XA01
ATC
erythropoietin; parenteral
89.0
14.9
16
*
C08CA13
ATC
lercanidipine; oral
4.4
14.8
48
145
N04.0
ICD-10 Finland
Nephrotic syndrome, minor glomerular abnormality
+∞
14.8
14
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
14.8
14
*
N03.0
ICD-10 Finland
Chronic nephritic syndrome, minor glomerular abnormality
+∞
14.8
14
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.5
14.4
26
47
M04AA01
ATC
allopurinol; systemic
4.3
14.0
46
140
B03XA03
ATC
methoxy polyethylene glycol-epoetin beta; parenteral
+∞
13.7
13
*
N03.5
ICD-10 Finland
Chronic nephritic syndrome, diffuse mesangiocapillary glomerulonephritis
+∞
13.7
13
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
153.2
13.7
14
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.0
13.3
33
80
L04AX01
ATC
azathioprine; systemic
14.1
13.1
22
18
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
76.5
12.8
14
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
141.2
12.6
13
*
M10.9
ICD-10 Finland
Gout, unspecified
5.5
12.4
27
58
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.8
12.4
32
80
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
12.3
103
567
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.3
11.7
73
334
N04.1
ICD-10 Finland
Nephrotic syndrome, focal and segmental glomerular lesions
+∞
11.6
11
*
V03AE03
ATC
lanthanum carbonate; oral
+∞
11.6
11
*
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
+∞
11.6
11
*
N18.4
ICD-10 Finland
Chronic kidney disease, stage 4
38.3
11.5
14
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.0
11.4
22
42
WW200
NOMESCO Finland
Immunization
15.5
11.3
18
13
H05BX01
ATC
cinacalcet; oral
47.1
11.1
13
*
C09CA01
ATC
losartan; oral
3.1
10.6
66
299
N06.2
ICD-10 Finland
Isolated proteinuria with specified morphological lesion, diffuse membranous glomerulonephritis
+∞
10.5
10
*
B05DB
ATC
Hypertonic solutions
+∞
10.5
10
*
KA9AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
10.5
10
*
B05DA
ATC
Isotonic solutions
+∞
10.5
10
*
N18.3
ICD-10 Finland
Chronic kidney disease, stage 3
16.1
10.3
16
11
C07AG02
ATC
carvedilol; oral
5.4
9.9
21
44
Z49.2
ICD-10 Finland
Other dialysis
106.4
9.5
10
*
C07AB02
ATC
metoprolol; systemic
3.2
9.5
48
190
M05BA04
ATC
alendronic acid; oral
4.9
9.2
22
51
321
Kela drug reimbursment
Paricalcitol and cinacalcet
39.3
9.1
11
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
9.6
9.1
18
21
B01AA03
ATC
warfarin; systemic
3.2
9.1
45
176
V03AE02
ATC
sevelamer; oral
95.1
8.5
9
*
PBM10
NOMESCO Finland
Closure of arteriovenous fistula of radial artery
+∞
8.4
8
*
7910X
ICD-9 Finland
Nonspecific findings on examination of urine, Proteinuria[PROTEINURIA NUD]
+∞
8.4
8
*
N17.9
ICD-10 Finland
Acute renal failure, unspecified
8.0
8.2
18
25
C03AA03
ATC
hydrochlorothiazide; oral
4.2
8.0
23
62
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
7.8
51
231
1XC02, ,
NOMESCO Finland
47.5
7.8
9
*
B01AB10
ATC
tinzaparin; parenteral
3.6
7.8
29
94
R4110
NOMESCO Finland
Physiotherapy
2.7
7.6
57
276
C08CA01
ATC
amlodipine; oral
2.6
7.5
79
452
L01AA01
ATC
cyclophosphamide; systemic
84.0
7.5
8
*
C08CA05
ATC
nifedipine; systemic
4.7
7.4
18
42
M10.3
ICD-10 Finland
Gout due to impairment of renal function
+∞
7.3
7
*
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
+∞
7.3
7
*
A12AA12
ATC
[U] calcium acetate
+∞
7.3
7
*
7151
FHL
Kidney transplantation
+∞
7.3
7
*
58200
ICD-8 Finland
Chronic nephritis, Cum uraemia
+∞
7.3
7
*
N08.2*D89.80
ICD-10 Finland
Immunoglobulin A (IgA) nephropathy
+∞
7.3
7
*
N04.3
ICD-10 Finland
Nephrotic syndrome, diffuse mesangial proliferative glomerulonephritis
+∞
7.3
7
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.4
7.3
29
98
C02CA01
ATC
prazosin; oral
10.8
7.2
13
13
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.4
7.1
19
48
ZXA00
NOMESCO Finland
Right side
2.6
6.7
55
276
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
6.6
40
172
KBV00
NOMESCO Finland
Insertion of stent into ureter
72.8
6.5
7
*
N39.1
ICD-10 Finland
Persistent proteinuria, unspecified
19.0
6.3
9
5
R50.9
ICD-10 Finland
Fever, unspecified
2.8
6.3
36
150
E78.5
ICD-10 Finland
Hyperlipidaemia, unspecified
3.2
6.3
28
101
H26.3
ICD-10 Finland
Drug-induced cataract
28.0
6.3
8
*
5829A
ICD-9 Finland
Chronic glomerulonephritis with unspecified pathological lesion in kidney[GLOMERULONEPHRITIS CHRONICA NUD ,EI NEFR SDR]
+∞
6.3
6
*
U88
ICPC
Glomerulonephritis/nephrosis
+∞
6.3
6
*
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
+∞
6.3
6
*
78900
ICD-8 Finland
Abnormal urinary constituents of unspecified cause, Albuminuria
+∞
6.3
6
*
PG5DE
NOMESCO Finland
Ultrasound examination of injection gate to artery or vein with Doppler method
+∞
6.3
6
*
5819X
ICD-9 Finland
Nephrotic syndrome with unspecified pathological lesion in kidney
+∞
6.3
6
*
58209
ICD-8 Finland
Chronic nephritis, Unspecified
+∞
6.3
6
*
R4190
NOMESCO Finland
Nutritional therapy
6.9
6.0
14
22
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
2.6e+00
2.6e+00
2.6e+00
—
3.3e+00
3.0e+00
2.8e+00
cases:25.85%
controls:2.59%
cases:24.49%
controls:2.31%
cases:10.88%
controls:0.88%
—
—
cases:16.44%
controls:0.68%
cases:38.62%
controls:2.98%
cases:47.45%
controls:5.16%
38
38
109
1432
36
34
111
1436
16
13
131
1457
—
24
10
122
1457
56
43
89
1399
65
71
72
1305
Outpatient Visit
OP [9202]
OP [9202]
9.5e-01
1.6e+00
1.9e+00
5.9e+00
2.0e+00
2.0e+00
1.7e+00
cases:74.83%
controls:53.61%
cases:71.43%
controls:32.93%
cases:34.01%
controls:7.35%
cases:61.22%
controls:0.41%
cases:37.67%
controls:7.84%
cases:80.00%
controls:34.12%
cases:90.51%
controls:63.59%
110
788
37
682
105
484
42
986
50
108
97
1362
90
6
57
1464
55
115
91
1352
116
492
29
950
124
875
13
501
enalapril; oral, parenteral
C09AA02 [21601786]
C09AA02 [21601786]
2.1e+00
2.3e+00
1.9e+00
—
3.0e+00
2.6e+00
2.3e+00
cases:22.45%
controls:3.54%
cases:17.69%
controls:2.04%
cases:4.08%
controls:0.61%
—
—
cases:6.16%
controls:0.34%
cases:23.45%
controls:2.22%
cases:28.47%
controls:3.71%
33
52
114
1418
26
30
121
1440
6
9
141
1461
—
9
5
137
1462
34
32
111
1410
39
51
98
1325
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
2.8e+00
3.1e+00
—
—
—
3.8e+00
2.5e+00
cases:18.37%
controls:1.36%
cases:9.52%
controls:0.48%
—
—
—
—
—
—
cases:20.00%
controls:0.55%
cases:21.17%
controls:2.11%
27
20
120
1450
14
7
133
1463
—
—
—
29
8
116
1434
29
29
108
1347
Internal Medicine
11 [38004456]
11 [38004456]
1.5e+00
1.7e+00
2.9e+00
—
2.6e+00
1.9e+00
1.6e+00
cases:48.98%
controls:18.37%
cases:32.65%
controls:8.16%
cases:19.73%
controls:1.29%
—
—
cases:13.70%
controls:1.16%
cases:34.48%
controls:7.49%
cases:54.74%
controls:20.28%
72
270
75
1200
48
120
99
1350
29
19
118
1451
—
20
17
126
1450
50
108
95
1334
75
279
62
1097
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
2.4e+00
3.1e+00
1.0e+50
—
—
3.2e+00
3.1e+00
cases:8.16%
controls:0.82%
cases:9.52%
controls:0.48%
cases:10.20%
controls:0.00%
—
—
—
—
cases:13.10%
controls:0.62%
cases:21.17%
controls:1.24%
12
12
135
1458
14
7
133
1463
15
0
132
1470
—
—
19
9
126
1433
29
17
108
1359
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
1.4e+00
2.0e+00
3.4e+00
—
—
2.3e+00
1.9e+00
cases:10.20%
controls:2.86%
cases:11.56%
controls:1.77%
cases:12.93%
controls:0.48%
—
—
—
—
cases:17.24%
controls:2.01%
cases:24.09%
controls:4.58%
15
42
132
1428
17
26
130
1444
19
7
128
1463
—
—
25
29
120
1413
33
63
104
1313
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
1.7e+00
1.7e+00
1.9e+00
—
1.9e+00
1.7e+00
1.1e+00
cases:15.65%
controls:3.40%
cases:12.24%
controls:2.59%
cases:4.76%
controls:0.75%
—
—
cases:5.48%
controls:0.82%
cases:15.86%
controls:3.19%
cases:18.25%
controls:6.69%
23
50
124
1420
18
38
129
1432
7
11
140
1459
—
8
12
138
1455
23
46
122
1396
25
92
112
1284
losartan; oral
C09CA01 [21601824]
C09CA01 [21601824]
1.1e+00
1.3e+00
2.2e+00
—
1.7e+00
2.0e+00
1.7e+00
cases:8.84%
controls:3.27%
cases:8.84%
controls:2.59%
cases:4.76%
controls:0.54%
—
—
cases:6.16%
controls:1.16%
cases:17.93%
controls:2.98%
cases:24.82%
controls:5.52%
13
48
134
1422
13
38
134
1432
7
8
140
1462
—
9
17
137
1450
26
43
119
1399
34
76
103
1300
atorvastatin; oral
C10AA05 [21601860]
C10AA05 [21601860]
9.4e-01
1.2e+00
1.8e+00
—
1.7e+00
1.9e+00
1.4e+00
cases:14.29%
controls:6.12%
cases:14.29%
controls:4.83%
cases:6.12%
controls:1.09%
—
—
cases:7.53%
controls:1.50%
cases:28.28%
controls:5.41%
cases:28.47%
controls:9.23%
21
90
126
1380
21
71
126
1399
9
16
138
1454
—
11
22
135
1445
41
78
104
1364
39
127
98
1249
felodipine; oral
C08CA02 [21601748]
C08CA02 [21601748]
1.9e+00
2.2e+00
—
—
—
2.4e+00
2.4e+00
cases:7.48%
controls:1.22%
cases:4.76%
controls:0.54%
—
—
—
—
—
—
cases:6.21%
controls:0.62%
cases:11.68%
controls:1.24%
11
18
136
1452
7
8
140
1462
—
—
—
9
9
136
1433
16
17
121
1359
Inpatient Hospital
21 [8717]
21 [8717]
1.1e+00
1.4e+00
2.1e+00
—
1.9e+00
1.1e+00
1.1e+00
cases:54.42%
controls:27.82%
cases:31.97%
controls:10.75%
cases:12.24%
controls:1.63%
—
—
cases:10.27%
controls:1.64%
cases:27.59%
controls:10.82%
cases:51.82%
controls:26.96%
80
409
67
1061
47
158
100
1312
18
24
129
1446
—
15
24
131
1443
40
156
105
1286
71
371
66
1005
Outpatient Hospital
22 [8756]
22 [8756]
9.4e-01
1.1e+00
2.2e+00
1.0e+50
2.1e+00
1.0e+00
9.3e-01
cases:40.82%
controls:21.16%
cases:19.73%
controls:7.48%
cases:6.12%
controls:0.75%
cases:4.76%
controls:0.00%
cases:8.90%
controls:1.23%
cases:16.55%
controls:6.80%
cases:39.42%
controls:20.35%
60
311
87
1159
29
110
118
1360
9
11
138
1459
7
0
140
1470
13
18
133
1449
24
98
121
1344
54
280
83
1096
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
2.2e+00
—
1.0e+50
—
—
3.4e+00
2.6e+00
cases:6.80%
controls:0.82%
—
—
cases:9.52%
controls:0.00%
—
—
—
—
cases:12.41%
controls:0.49%
cases:16.79%
controls:1.45%
10
12
137
1458
—
14
0
133
1470
—
—
18
7
127
1435
23
20
114
1356
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
1.8e+00
2.0e+00
—
—
—
2.0e+00
2.1e+00
cases:8.16%
controls:1.50%
cases:6.80%
controls:1.02%
—
—
—
—
—
—
cases:7.59%
controls:1.11%
cases:13.87%
controls:1.89%
12
22
135
1448
10
15
137
1455
—
—
—
11
16
134
1426
19
26
118
1350
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
4.4e-01
1.1e+00
1.1e+00
2.2e+00
1.3e+00
1.8e+00
1.4e+00
cases:88.44%
controls:83.06%
cases:88.44%
controls:71.97%
cases:59.86%
controls:33.74%
cases:14.97%
controls:1.84%
cases:65.07%
controls:34.29%
cases:94.48%
controls:74.27%
cases:97.81%
controls:91.57%
130
1221
17
249
130
1058
17
412
88
496
59
974
22
27
125
1443
95
503
51
964
137
1071
8
371
134
1260
3
116
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
2.1e+00
2.5e+00
—
—
—
—
2.2e+00
cases:5.44%
controls:0.68%
cases:4.76%
controls:0.41%
—
—
—
—
—
—
—
—
cases:9.49%
controls:1.16%
8
10
139
1460
7
6
140
1464
—
—
—
—
13
16
124
1360
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.4e-01
9.3e-01
2.3e+00
—
2.0e+00
1.3e+00
4.4e-01
cases:12.24%
controls:10.82%
cases:16.33%
controls:7.14%
cases:10.20%
controls:1.16%
—
—
cases:6.16%
controls:0.89%
cases:20.00%
controls:6.66%
cases:24.82%
controls:17.59%
18
159
129
1311
24
105
123
1365
15
17
132
1453
—
9
13
137
1454
29
96
116
1346
34
242
103
1134
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
9.5e-01
2.2e+00
—
—
—
2.4e+00
1.8e+00
cases:10.20%
controls:4.22%
cases:13.61%
controls:1.70%
—
—
—
—
—
—
cases:15.86%
controls:1.73%
cases:22.63%
controls:4.43%
15
62
132
1408
20
25
127
1445
—
—
—
23
25
122
1417
31
61
106
1315
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
2.1e+00
2.3e+00
—
—
—
—
1.9e+00
cases:5.44%
controls:0.68%
cases:4.76%
controls:0.48%
—
—
—
—
—
—
—
—
cases:8.76%
controls:1.38%
8
10
139
1460
7
7
140
1463
—
—
—
—
12
19
125
1357
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
2.9e-01
1.2e+00
3.1e+00
—
—
1.2e+00
8.9e-01
cases:7.48%
controls:5.71%
cases:9.52%
controls:2.99%
cases:8.16%
controls:0.41%
—
—
—
—
cases:9.66%
controls:3.12%
cases:18.98%
controls:8.79%
11
84
136
1386
14
44
133
1426
12
6
135
1464
—
—
14
45
131
1397
26
121
111
1255
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
9.8e-01
2.5e+00
—
—
—
2.0e+00
1.8e+00
cases:5.44%
controls:2.11%
cases:8.16%
controls:0.75%
—
—
—
—
—
—
cases:6.90%
controls:1.04%
cases:14.60%
controls:2.83%
8
31
139
1439
12
11
135
1459
—
—
—
10
15
135
1427
20
39
117
1337
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
2.1e+00
2.1e+00
—
—
—
—
1.8e+00
cases:5.44%
controls:0.68%
cases:4.76%
controls:0.61%
—
—
—
—
—
—
—
—
cases:8.76%
controls:1.53%
8
10
139
1460
7
9
140
1461
—
—
—
—
12
21
125
1355
metoprolol; oral, parenteral
C07AB02 [21601684]
C07AB02 [21601684]
1.5e+00
1.3e+00
—
—
1.7e+00
1.6e+00
1.6e+00
cases:15.65%
controls:4.08%
cases:10.88%
controls:3.33%
—
—
—
—
cases:3.42%
controls:0.61%
cases:14.48%
controls:3.19%
cases:18.25%
controls:4.29%
23
60
124
1410
16
49
131
1421
—
—
5
9
141
1458
21
46
124
1396
25
59
112
1317
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
2.9e+00
—
—
—
—
—
2.9e+00
cases:6.12%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:8.76%
controls:0.51%
9
5
138
1465
—
—
—
—
—
12
7
125
1369
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
9.8e-01
1.9e+00
—
—
—
2.2e+00
1.8e+00
cases:9.52%
controls:3.81%
cases:10.20%
controls:1.70%
—
—
—
—
—
—
cases:12.41%
controls:1.53%
cases:20.44%
controls:4.22%
14
56
133
1414
15
25
132
1445
—
—
—
18
22
127
1420
28
58
109
1318
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
14683-7 [3009508]
1.1e+00
2.1e+00
1.0e+50
—
—
2.1e+00
1.5e+00
cases:7.48%
controls:2.65%
cases:10.88%
controls:1.50%
cases:8.84%
controls:0.00%
—
—
—
—
cases:12.41%
controls:1.66%
cases:22.63%
controls:6.10%
11
39
136
1431
16
22
131
1448
13
0
134
1470
—
—
18
24
127
1418
31
84
106
1292
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
8.8e-01
1.3e+00
2.3e+00
1.0e+50
—
1.1e+00
5.8e-01
cases:21.09%
controls:10.00%
cases:13.61%
controls:3.95%
cases:8.16%
controls:0.88%
cases:7.48%
controls:0.00%
—
—
cases:11.72%
controls:4.44%
cases:24.09%
controls:15.04%
31
147
116
1323
20
58
127
1412
12
13
135
1457
11
0
136
1470
—
17
64
128
1378
33
207
104
1169
amlodipine; oral
C08CA01 [21601747]
C08CA01 [21601747]
1.3e+00
1.3e+00
—
—
1.7e+00
1.5e+00
1.3e+00
cases:14.29%
controls:4.29%
cases:12.93%
controls:3.95%
—
—
—
—
cases:4.79%
controls:0.95%
cases:17.24%
controls:4.37%
cases:25.55%
controls:8.28%
21
63
126
1407
19
58
128
1412
—
—
7
14
139
1453
25
63
120
1379
35
114
102
1262
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
1.1e+00
1.4e+00
—
—
—
1.7e+00
1.2e+00
cases:13.61%
controls:4.76%
cases:7.48%
controls:1.97%
—
—
—
—
—
—
cases:8.28%
controls:1.60%
cases:18.25%
controls:6.32%
20
70
127
1400
11
29
136
1441
—
—
—
12
23
133
1419
25
87
112
1289
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
1.6e-01
8.0e-01
2.6e+00
—
1.9e+00
9.2e-01
4.1e-01
cases:9.52%
controls:8.23%
cases:13.61%
controls:6.60%
cases:12.93%
controls:1.09%
—
—
cases:4.79%
controls:0.75%
cases:14.48%
controls:6.31%
cases:21.17%
controls:15.19%
14
121
133
1349
20
97
127
1373
19
16
128
1454
—
7
11
139
1456
21
91
124
1351
29
209
108
1167
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
32294-1 [3020682]
1.1e+00
2.0e+00
—
—
—
2.0e+00
1.4e+00
cases:7.48%
controls:2.65%
cases:10.88%
controls:1.63%
—
—
—
—
—
—
cases:12.41%
controls:1.87%
cases:22.63%
controls:6.61%
11
39
136
1431
16
24
131
1446
—
—
—
18
27
127
1415
31
91
106
1285
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
1.2e+00
1.7e+00
1.0e+50
—
1.0e+50
2.0e+00
1.6e+00
cases:6.80%
controls:2.24%
cases:7.48%
controls:1.43%
cases:6.80%
controls:0.00%
—
—
cases:3.42%
controls:0.00%
cases:11.03%
controls:1.60%
cases:20.44%
controls:4.80%
10
33
137
1437
11
21
136
1449
10
0
137
1470
—
5
0
141
1467
16
23
129
1419
28
66
109
1310
lercanidipine; oral
C08CA13 [21601759]
C08CA13 [21601759]
1.7e+00
1.3e+00
—
—
—
1.5e+00
2.1e+00
cases:7.48%
controls:1.43%
cases:4.76%
controls:1.29%
—
—
—
—
—
—
cases:6.21%
controls:1.46%
cases:16.06%
controls:2.25%
11
21
136
1449
7
19
140
1451
—
—
—
9
21
136
1421
22
31
115
1345
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
2731-8 [3000067]
2.8e+00
—
1.0e+50
—
—
—
2.6e+00
cases:6.12%
controls:0.41%
—
—
cases:4.76%
controls:0.00%
—
—
—
—
—
—
cases:10.95%
controls:0.94%
9
6
138
1464
—
7
0
140
1470
—
—
—
15
13
122
1363
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1754-1 [3012516]
9.0e-01
2.0e+00
1.0e+50
—
—
1.9e+00
1.4e+00
cases:6.12%
controls:2.59%
cases:10.88%
controls:1.56%
cases:7.48%
controls:0.00%
—
—
—
—
cases:11.72%
controls:2.01%
cases:20.44%
controls:5.96%
9
38
138
1432
16
23
131
1447
11
0
136
1470
—
—
17
29
128
1413
28
82
109
1294
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
9.8e-01
1.9e+00
1.0e+50
—
—
1.8e+00
1.6e+00
cases:5.44%
controls:2.11%
cases:6.80%
controls:1.09%
cases:6.12%
controls:0.00%
—
—
—
—
cases:8.28%
controls:1.46%
cases:17.52%
controls:4.14%
8
31
139
1439
10
16
137
1454
9
0
138
1470
—
—
12
21
133
1421
24
57
113
1319
Gastroenterology
10 [38004455]
10 [38004455]
1.5e+00
7.5e-01
—
—
—
2.5e+00
1.2e+00
cases:11.56%
controls:2.72%
cases:3.40%
controls:1.63%
—
—
—
—
—
—
cases:8.97%
controls:0.83%
cases:10.95%
controls:3.42%
17
40
130
1430
5
24
142
1446
—
—
—
13
12
132
1430
15
47
122
1329
Hematology
82 [38004501]
82 [38004501]
2.5e+00
2.0e+00
—
—
—
—
2.7e+00
cases:4.76%
controls:0.41%
cases:3.40%
controls:0.48%
—
—
—
—
—
—
—
—
cases:7.30%
controls:0.51%
7
6
140
1464
5
7
142
1463
—
—
—
—
10
7
127
1369
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.1e-01
6.5e-01
2.3e+00
—
2.1e+00
8.7e-01
3.5e-01
cases:12.24%
controls:11.16%
cases:16.33%
controls:9.25%
cases:15.65%
controls:1.90%
—
—
cases:8.90%
controls:1.23%
cases:20.00%
controls:9.50%
cases:28.47%
controls:21.88%
18
164
129
1306
24
136
123
1334
23
28
124
1442
—
13
18
133
1449
29
137
116
1305
39
301
98
1075
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.1e-01
6.4e-01
2.3e+00
—
2.0e+00
8.7e-01
3.6e-01
cases:12.24%
controls:11.09%
cases:16.33%
controls:9.32%
cases:15.65%
controls:1.84%
—
—
cases:8.22%
controls:1.23%
cases:20.00%
controls:9.50%
cases:28.47%
controls:21.73%
18
163
129
1307
24
137
123
1333
23
27
124
1443
—
12
18
134
1449
29
137
116
1305
39
299
98
1077
candesartan; oral
C09CA06 [21601829]
C09CA06 [21601829]
9.0e-01
1.0e+00
—
—
2.1e+00
1.8e+00
1.2e+00
cases:6.12%
controls:2.59%
cases:5.44%
controls:2.04%
—
—
—
—
cases:4.79%
controls:0.61%
cases:10.34%
controls:1.87%
cases:12.41%
controls:4.29%
9
38
138
1432
8
30
139
1440
—
—
7
9
139
1458
15
27
130
1415
17
59
120
1317
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
8.6e-01
1.7e+00
1.0e+50
—
—
1.7e+00
1.6e+00
cases:5.44%
controls:2.38%
cases:6.80%
controls:1.29%
cases:6.12%
controls:0.00%
—
—
—
—
cases:8.28%
controls:1.60%
cases:18.25%
controls:4.43%
8
35
139
1435
10
19
137
1451
9
0
138
1470
—
—
12
23
133
1419
25
61
112
1315
Nephrology
39 [38004479]
39 [38004479]
4.7e+00
—
—
1.0e+50
—
—
—
cases:34.69%
controls:0.48%
—
—
—
—
cases:58.50%
controls:0.00%
—
—
—
—
—
—
51
7
96
1463
—
—
86
0
61
1470
—
—
—
ramipril; oral
C09AA05 [21601789]
C09AA05 [21601789]
6.3e-01
1.3e+00
1.5e+00
—
2.0e+00
1.4e+00
8.7e-01
cases:6.80%
controls:3.74%
cases:12.24%
controls:3.74%
cases:4.76%
controls:1.09%
—
—
cases:6.85%
controls:0.95%
cases:13.79%
controls:3.88%
cases:13.87%
controls:6.32%
10
55
137
1415
18
55
129
1415
7
16
140
1454
—
10
14
136
1453
20
56
125
1386
19
87
118
1289
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
9.1e-01
1.8e+00
1.0e+50
—
—
1.6e+00
1.2e+00
cases:4.76%
controls:1.97%
cases:5.44%
controls:0.95%
cases:3.40%
controls:0.00%
—
—
—
—
cases:5.52%
controls:1.11%
cases:10.95%
controls:3.42%
7
29
140
1441
8
14
139
1456
5
0
142
1470
—
—
8
16
137
1426
15
47
122
1329
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-6.3e-03
5.0e-01
2.1e+00
—
1.7e+00
7.7e-01
2.2e-01
cases:12.24%
controls:12.31%
cases:16.33%
controls:10.61%
cases:15.65%
controls:2.31%
—
—
cases:7.53%
controls:1.43%
cases:20.00%
controls:10.33%
cases:28.47%
controls:24.13%
18
181
129
1289
24
156
123
1314
23
34
124
1436
—
11
21
135
1446
29
149
116
1293
39
332
98
1044
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
9.8e-01
1.7e+00
—
—
—
1.4e+00
1.5e+00
cases:6.12%
controls:2.38%
cases:5.44%
controls:1.09%
—
—
—
—
—
—
cases:6.90%
controls:1.73%
cases:16.79%
controls:4.51%
9
35
138
1435
8
16
139
1454
—
—
—
10
25
135
1417
23
62
114
1314
Emergency Room Visit
ER [9203]
ER [9203]
5.6e-01
1.0e+00
1.9e+00
1.0e+50
—
7.9e-01
8.3e-01
cases:37.41%
controls:25.37%
cases:20.41%
controls:8.64%
cases:8.16%
controls:1.29%
cases:4.76%
controls:0.00%
—
—
cases:17.93%
controls:9.02%
cases:47.45%
controls:28.27%
55
373
92
1097
30
127
117
1343
12
19
135
1451
7
0
140
1470
—
26
130
119
1312
65
389
72
987
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.2e+00
1.7e+00
—
1.0e+50
—
1.3e+00
1.7e+00
cases:11.56%
controls:3.88%
cases:6.80%
controls:1.36%
—
—
cases:4.08%
controls:0.00%
—
—
cases:6.21%
controls:1.73%
cases:23.36%
controls:5.45%
17
57
130
1413
10
20
137
1450
—
6
0
141
1470
—
9
25
136
1417
32
75
105
1301
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
2.3e+00
—
—
—
—
—
2.1e+00
cases:4.08%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:0.73%
6
6
141
1464
—
—
—
—
—
8
10
129
1366
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
3.2e-01
1.2e+00
2.0e+00
—
—
1.2e+00
7.8e-01
cases:8.84%
controls:6.60%
cases:9.52%
controls:2.99%
cases:4.08%
controls:0.54%
—
—
—
—
cases:8.97%
controls:2.98%
cases:18.25%
controls:9.30%
13
97
134
1373
14
44
133
1426
6
8
141
1462
—
—
13
43
132
1399
25
128
112
1248
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
3.3e-01
8.7e-01
2.6e+00
—
—
1.5e+00
7.3e-01
cases:9.52%
controls:7.01%
cases:10.20%
controls:4.56%
cases:10.20%
controls:0.82%
—
—
—
—
cases:15.86%
controls:3.88%
cases:21.17%
controls:11.41%
14
103
133
1367
15
67
132
1403
15
12
132
1458
—
—
23
56
122
1386
29
157
108
1219
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
—
—
—
—
1.0e+50
—
4.0e+00
—
—
—
—
—
—
—
—
cases:4.79%
controls:0.00%
—
—
cases:21.90%
controls:0.51%
—
—
—
—
7
0
139
1467
—
30
7
107
1369
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
1.1e+00
1.8e+00
1.0e+50
—
—
2.0e+00
1.8e+00
cases:4.08%
controls:1.43%
cases:4.08%
controls:0.68%
cases:4.76%
controls:0.00%
—
—
—
—
cases:6.21%
controls:0.90%
cases:13.87%
controls:2.54%
6
21
141
1449
6
10
141
1460
7
0
140
1470
—
—
9
13
136
1429
19
35
118
1341
Chronic kidney disease, unspecified
N18.9 [45553438]
N18.9 [45553438]
—
—
—
—
—
—
3.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.14%
controls:0.44%
—
—
—
—
—
—
18
6
119
1370
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
1.1e+00
2.0e+00
—
—
—
1.5e+00
1.5e+00
cases:4.76%
controls:1.56%
cases:6.12%
controls:0.88%
—
—
—
—
—
—
cases:4.14%
controls:0.97%
cases:12.41%
controls:3.20%
7
23
140
1447
9
13
138
1457
—
—
—
6
14
139
1428
17
44
120
1332
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
9.5e-01
7.8e-01
2.3e+00
—
—
1.2e+00
1.1e+00
cases:8.16%
controls:3.33%
cases:4.08%
controls:1.90%
cases:4.76%
controls:0.48%
—
—
—
—
cases:6.21%
controls:1.94%
cases:13.87%
controls:5.31%
12
49
135
1421
6
28
141
1442
7
7
140
1463
—
—
9
28
136
1414
19
73
118
1303
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
9.5e-01
7.8e-01
2.3e+00
—
—
1.2e+00
1.0e+00
cases:8.16%
controls:3.33%
cases:4.08%
controls:1.90%
cases:4.76%
controls:0.48%
—
—
—
—
cases:6.21%
controls:1.87%
cases:13.87%
controls:5.38%
12
49
135
1421
6
28
141
1442
7
7
140
1463
—
—
9
27
136
1415
19
74
118
1302
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
9.5e-01
7.8e-01
2.3e+00
—
—
1.2e+00
1.0e+00
cases:8.16%
controls:3.33%
cases:4.08%
controls:1.90%
cases:4.76%
controls:0.48%
—
—
—
—
cases:6.21%
controls:1.94%
cases:13.87%
controls:5.52%
12
49
135
1421
6
28
141
1442
7
7
140
1463
—
—
9
28
136
1414
19
76
118
1300
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
-8.2e-02
4.6e-01
1.9e+00
1.0e+50
1.5e+00
6.6e-01
1.0e-01
cases:12.93%
controls:13.88%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.93%
cases:3.40%
controls:0.00%
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.44%
cases:27.74%
controls:25.73%
19
204
128
1266
25
169
122
1301
24
43
123
1427
5
0
142
1470
12
30
134
1437
29
165
116
1277
38
354
99
1022
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
7.9e-01
5.6e-01
2.2e+00
—
—
1.1e+00
1.1e+00
cases:7.48%
controls:3.54%
cases:4.08%
controls:2.38%
cases:4.76%
controls:0.54%
—
—
—
—
cases:6.21%
controls:2.08%
cases:16.06%
controls:5.96%
11
52
136
1418
6
35
141
1435
7
8
140
1462
—
—
9
30
136
1412
22
82
115
1294
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
9.9e-01
7.5e-01
2.3e+00
—
—
1.2e+00
9.6e-01
cases:8.16%
controls:3.20%
cases:4.08%
controls:1.97%
cases:4.76%
controls:0.48%
—
—
—
—
cases:6.21%
controls:1.94%
cases:13.87%
controls:5.81%
12
47
135
1423
6
29
141
1441
7
7
140
1463
—
—
9
28
136
1414
19
80
118
1296
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
-7.6e-02
4.6e-01
1.8e+00
—
1.5e+00
6.5e-01
9.9e-02
cases:12.93%
controls:13.81%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.51%
cases:27.74%
controls:25.80%
19
203
128
1267
25
169
122
1301
24
44
123
1426
—
12
30
134
1437
29
166
116
1276
38
355
99
1021
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
-7.6e-02
4.6e-01
1.8e+00
—
1.5e+00
6.6e-01
1.0e-01
cases:12.93%
controls:13.81%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.44%
cases:27.74%
controls:25.73%
19
203
128
1267
25
169
122
1301
24
44
123
1426
—
12
30
134
1437
29
165
116
1277
38
354
99
1022
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
-8.8e-02
4.6e-01
1.8e+00
—
1.5e+00
6.5e-01
9.9e-02
cases:12.93%
controls:13.95%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.51%
cases:27.74%
controls:25.80%
19
205
128
1265
25
169
122
1301
24
44
123
1426
—
12
30
134
1437
29
166
116
1276
38
355
99
1021
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
-8.2e-02
4.6e-01
1.8e+00
—
1.5e+00
6.5e-01
9.9e-02
cases:12.93%
controls:13.88%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.51%
cases:27.74%
controls:25.80%
19
204
128
1266
25
169
122
1301
24
44
123
1426
—
12
30
134
1437
29
166
116
1276
38
355
99
1021
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
-8.8e-02
4.6e-01
1.8e+00
—
1.5e+00
6.5e-01
9.9e-02
cases:12.93%
controls:13.95%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.04%
cases:20.00%
controls:11.58%
cases:27.74%
controls:25.80%
19
205
128
1265
25
169
122
1301
24
44
123
1426
—
12
30
134
1437
29
167
116
1275
38
355
99
1021
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
-8.8e-02
4.6e-01
1.8e+00
—
1.4e+00
6.5e-01
9.5e-02
cases:12.93%
controls:13.95%
cases:17.01%
controls:11.50%
cases:16.33%
controls:2.99%
—
—
cases:8.22%
controls:2.11%
cases:20.00%
controls:11.58%
cases:27.74%
controls:25.87%
19
205
128
1265
25
169
122
1301
24
44
123
1426
—
12
31
134
1436
29
167
116
1275
38
356
99
1020
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
7.9e-01
5.6e-01
2.1e+00
—
—
1.1e+00
1.1e+00
cases:7.48%
controls:3.54%
cases:4.08%
controls:2.38%
cases:4.76%
controls:0.61%
—
—
—
—
cases:6.21%
controls:2.15%
cases:16.06%
controls:6.03%
11
52
136
1418
6
35
141
1435
7
9
140
1461
—
—
9
31
136
1411
22
83
115
1293
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.03%
controls:0.36%
—
—
—
—
—
—
11
5
126
1371
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
1.6e-01
1.8e+00
—
—
—
1.1e+00
1.3e+00
cases:3.40%
controls:2.93%
cases:6.12%
controls:1.02%
—
—
—
—
—
—
cases:4.83%
controls:1.60%
cases:14.60%
controls:4.51%
5
43
142
1427
9
15
138
1455
—
—
—
7
23
138
1419
20
62
117
1314
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
7.9e-01
5.6e-01
2.1e+00
—
—
1.0e+00
1.0e+00
cases:7.48%
controls:3.54%
cases:4.08%
controls:2.38%
cases:4.76%
controls:0.61%
—
—
—
—
cases:6.21%
controls:2.29%
cases:16.06%
controls:6.40%
11
52
136
1418
6
35
141
1435
7
9
140
1461
—
—
9
33
136
1409
22
88
115
1288
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
7.3e-01
5.3e-01
2.0e+00
—
—
1.2e+00
1.1e+00
cases:7.48%
controls:3.74%
cases:4.08%
controls:2.45%
cases:4.76%
controls:0.68%
—
—
—
—
cases:6.90%
controls:2.15%
cases:16.79%
controls:6.32%
11
55
136
1415
6
36
141
1434
7
10
140
1460
—
—
10
31
135
1411
23
87
114
1289
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
3.1e+00
—
—
—
—
—
—
cases:6.80%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
10
5
137
1465
—
—
—
—
—
—
General Surgery
2 [38004447]
2 [38004447]
3.1e-01
5.9e-01
2.3e+00
—
1.2e+00
6.2e-01
7.4e-01
cases:25.85%
controls:20.41%
cases:10.88%
controls:6.33%
cases:7.48%
controls:0.82%
—
—
cases:4.11%
controls:1.30%
cases:11.72%
controls:6.66%
cases:29.93%
controls:16.86%
38
300
109
1170
16
93
131
1377
11
12
136
1458
—
6
19
140
1448
17
96
128
1346
41
232
96
1144
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
7.8e-01
1.6e+00
—
—
—
1.6e+00
1.4e+00
cases:4.08%
controls:1.90%
cases:4.76%
controls:0.95%
—
—
—
—
—
—
cases:5.52%
controls:1.11%
cases:10.95%
controls:3.05%
6
28
141
1442
7
14
140
1456
—
—
—
8
16
137
1426
15
42
122
1334
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
4.2e-01
1.9e-01
6.4e-01
3.0e+00
3.2e-01
3.4e-01
4.9e-01
cases:43.54%
controls:33.61%
cases:29.25%
controls:25.51%
cases:17.01%
controls:9.73%
cases:12.24%
controls:0.68%
cases:13.01%
controls:9.82%
cases:37.24%
controls:29.61%
cases:63.50%
controls:51.53%
64
494
83
976
43
375
104
1095
25
143
122
1327
18
10
129
1460
19
144
127
1323
54
427
91
1015
87
709
50
667
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
8.1e-01
8.7e-01
1.5e+00
—
1.5e+00
1.3e+00
8.7e-01
cases:17.69%
controls:8.71%
cases:12.93%
controls:5.85%
cases:6.12%
controls:1.50%
—
—
cases:5.48%
controls:1.23%
cases:18.62%
controls:5.83%
cases:25.55%
controls:12.57%
26
128
121
1342
19
86
128
1384
9
22
138
1448
—
8
18
138
1449
27
84
118
1358
35
173
102
1203
moxonidine; oral
C02AC05 [21600401]
C02AC05 [21600401]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:0.36%
—
—
—
—
—
—
9
5
128
1371
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
1.9e+00
—
—
—
—
—
3.0e+00
cases:3.40%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:0.36%
5
8
142
1462
—
—
—
—
—
9
5
128
1371
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
1.0e+00
1.6e+00
—
—
—
—
1.1e+00
cases:6.12%
controls:2.31%
cases:6.12%
controls:1.29%
—
—
—
—
—
—
—
—
cases:13.14%
controls:4.58%
9
34
138
1436
9
19
138
1451
—
—
—
—
18
63
119
1313
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
14646-4 [3023602]
1.6e-01
6.5e-01
1.9e+00
—
—
8.9e-01
3.8e-01
cases:11.56%
controls:10.00%
cases:10.88%
controls:5.99%
cases:5.44%
controls:0.88%
—
—
—
—
cases:15.17%
controls:6.87%
cases:27.01%
controls:20.20%
17
147
130
1323
16
88
131
1382
8
13
139
1457
—
—
22
99
123
1343
37
278
100
1098
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
1.1e-01
5.0e-01
1.9e+00
—
1.5e+00
8.1e-01
2.4e-01
cases:12.93%
controls:11.77%
cases:12.93%
controls:8.23%
cases:12.24%
controls:2.11%
—
—
cases:4.79%
controls:1.09%
cases:17.24%
controls:8.46%
cases:24.82%
controls:20.64%
19
173
128
1297
19
121
128
1349
18
31
129
1439
—
7
16
139
1451
25
122
120
1320
34
284
103
1092
Chronic hypertension
205 [2001600203]
205 [2001600203]
1.0e+00
—
—
—
—
2.7e+00
—
cases:8.16%
controls:3.06%
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.35%
—
—
12
45
135
1425
—
—
—
—
7
5
138
1437
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
2.3e-01
1.5e+00
—
—
—
1.1e+00
1.1e+00
cases:4.76%
controls:3.81%
cases:8.16%
controls:1.90%
—
—
—
—
—
—
cases:6.21%
controls:2.15%
cases:19.71%
controls:7.85%
7
56
140
1414
12
28
135
1442
—
—
—
9
31
136
1411
27
108
110
1268
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
2.5e-01
1.5e+00
—
—
—
1.1e+00
1.0e+00
cases:4.76%
controls:3.74%
cases:8.16%
controls:1.90%
—
—
—
—
—
—
cases:6.21%
controls:2.08%
cases:18.98%
controls:7.70%
7
55
140
1415
12
28
135
1442
—
—
—
9
30
136
1412
26
106
111
1270
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.2e+00
7.2e-01
2.3e+00
—
—
1.2e+00
1.3e+00
cases:20.41%
controls:7.07%
cases:4.76%
controls:2.38%
cases:3.40%
controls:0.34%
—
—
—
—
cases:7.59%
controls:2.36%
cases:21.17%
controls:6.61%
30
104
117
1366
7
35
140
1435
5
5
142
1465
—
—
11
34
134
1408
29
91
108
1285
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.36%
—
—
—
—
—
—
6
5
131
1371
Acute tubulo-interstitial nephritis
N10 [45543856]
N10 [45543856]
2.5e+00
—
—
—
—
—
1.7e+00
cases:4.08%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:1.02%
6
5
141
1465
—
—
—
—
—
7
14
130
1362
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
2.7e-01
1.4e+00
—
—
—
1.1e+00
1.0e+00
cases:4.76%
controls:3.67%
cases:8.16%
controls:2.04%
—
—
—
—
—
—
cases:6.21%
controls:2.15%
cases:19.71%
controls:7.99%
7
54
140
1416
12
30
135
1440
—
—
—
9
31
136
1411
27
110
110
1266
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
1.1e+00
—
—
—
—
2.4e+00
8.4e-01
cases:7.48%
controls:2.72%
—
—
—
—
—
—
—
—
cases:7.59%
controls:0.76%
cases:5.84%
controls:2.62%
11
40
136
1430
—
—
—
—
11
11
134
1431
8
36
129
1340
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.44%
—
—
—
—
—
—
6
6
131
1370
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
33863-2 [3030366]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.44%
—
—
—
—
—
—
6
6
131
1370
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
29953-7 [3037522]
2.3e+00
—
—
—
—
—
—
cases:4.76%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
7
7
140
1463
—
—
—
—
—
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
-1.0e+50
—
—
—
—
-1.0e+50
2.3e+00
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:3.65%
controls:0.36%
0
9
147
1461
—
—
—
—
0
5
145
1437
5
5
132
1371
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
2.3e+00
—
—
—
—
—
—
cases:4.08%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
141
1464
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2020-6 [3023024]
2.3e+00
—
—
—
—
—
—
cases:4.08%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
141
1464
—
—
—
—
—
—
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
2.0e+00
—
—
—
—
—
2.3e+00
cases:3.40%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:10.22%
controls:1.09%
5
7
142
1463
—
—
—
—
—
14
15
123
1361
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.0e+00
1.5e+00
—
—
—
—
1.2e+00
cases:12.24%
controls:4.69%
cases:3.40%
controls:0.82%
—
—
—
—
—
—
—
—
cases:12.41%
controls:4.14%
18
69
129
1401
5
12
142
1458
—
—
—
—
17
57
120
1319
Oral Surgery
19 [38004464]
19 [38004464]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.58%
—
—
—
—
—
—
7
8
130
1368
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.51%
—
—
—
—
—
—
6
7
131
1369
Seborrhoeic keratosis
L82 [45548208]
L82 [45548208]
2.2e+00
—
—
—
—
—
—
cases:4.08%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
141
1463
—
—
—
—
—
—
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
72720-6 [43055554]
2.2e+00
—
—
—
—
—
—
cases:4.08%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
141
1463
—
—
—
—
—
—
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
4.4e-01
2.2e+00
—
—
—
-1.0e+50
6.4e-01
cases:4.76%
controls:3.13%
cases:4.08%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:7.30%
controls:4.00%
7
46
140
1424
6
7
141
1463
—
—
—
0
7
145
1435
10
55
127
1321
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
5.0e-01
1.1e+00
—
—
—
1.1e+00
1.0e+00
cases:10.88%
controls:6.87%
cases:8.84%
controls:3.06%
—
—
—
—
—
—
cases:8.97%
controls:3.33%
cases:19.71%
controls:8.07%
16
101
131
1369
13
45
134
1425
—
—
—
13
48
132
1394
27
111
110
1265
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
5.7e-01
1.1e+00
—
—
—
1.1e+00
1.0e+00
cases:11.56%
controls:6.87%
cases:8.84%
controls:3.06%
—
—
—
—
—
—
cases:8.97%
controls:3.33%
cases:19.71%
controls:8.07%
17
101
130
1369
13
45
134
1425
—
—
—
13
48
132
1394
27
111
110
1265
fluvastatin; oral
C10AA04 [21601859]
C10AA04 [21601859]
1.2e+00
1.7e+00
-1.0e+50
—
—
2.1e+00
1.6e+00
cases:3.40%
controls:1.02%
cases:4.76%
controls:0.88%
cases:0.00%
controls:0.41%
—
—
—
—
cases:6.21%
controls:0.76%
cases:5.84%
controls:1.24%
5
15
142
1455
7
13
140
1457
0
6
147
1464
—
—
9
11
136
1431
8
17
129
1359
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
2.3e+00
—
—
—
—
—
2.1e+00
cases:3.40%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:7.30%
controls:0.94%
5
5
142
1465
—
—
—
—
—
10
13
127
1363
carvedilol; oral
C07AG02 [21601700]
C07AG02 [21601700]
—
1.5e+00
-1.0e+50
—
—
1.6e+00
2.1e+00
—
—
cases:3.40%
controls:0.82%
cases:0.00%
controls:0.41%
—
—
—
—
cases:3.45%
controls:0.69%
cases:7.30%
controls:0.94%
—
5
12
142
1458
0
6
147
1464
—
—
5
10
140
1432
10
13
127
1363
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
1.3e+00
—
—
—
—
—
2.1e+00
cases:4.08%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.65%
6
17
141
1453
—
—
—
—
—
7
9
130
1367
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
-1.1e-01
5.6e-01
2.1e+00
—
—
2.9e-01
1.0e-01
cases:9.52%
controls:10.54%
cases:10.20%
controls:6.12%
cases:6.12%
controls:0.82%
—
—
—
—
cases:8.28%
controls:6.31%
cases:20.44%
controls:18.82%
14
155
133
1315
15
90
132
1380
9
12
138
1458
—
—
12
91
133
1351
28
259
109
1117
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
J07AL02 [21601313]
-1.0e+50
—
—
—
—
—
2.1e+00
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.58%
0
5
147
1465
—
—
—
—
—
6
8
131
1368
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
2.0e+00
—
—
—
—
—
1.7e+00
cases:4.08%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:0.65%
6
8
141
1462
—
—
—
—
—
5
9
132
1367
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
2.0e+00
—
—
—
—
—
—
cases:4.08%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
141
1462
—
—
—
—
—
—
Examination of ears and hearing
Z01.1 [45547279]
Z01.1 [45547279]
2.0e+00
—
—
—
—
—
—
cases:4.08%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
141
1462
—
—
—
—
—
—
warfarin; oral, parenteral
B01AA03 [21600965]
B01AA03 [21600965]
4.1e-01
5.3e-01
—
—
2.0e+00
9.9e-01
8.2e-01
cases:5.44%
controls:3.67%
cases:5.44%
controls:3.27%
—
—
—
—
cases:5.48%
controls:0.75%
cases:9.66%
controls:3.81%
cases:11.68%
controls:5.52%
8
54
139
1416
8
48
139
1422
—
—
8
11
138
1456
14
55
131
1387
16
76
121
1300
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
51484-4 [3030981]
—
—
1.0e+50
—
—
2.3e+00
2.0e+00
—
—
—
—
cases:3.40%
controls:0.00%
—
—
—
—
cases:3.45%
controls:0.35%
cases:8.76%
controls:1.24%
—
—
5
0
142
1470
—
—
5
5
140
1437
12
17
125
1359
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
2.5e-01
5.9e-01
1.9e+00
—
—
6.0e-01
1.2e-01
cases:10.20%
controls:8.16%
cases:9.52%
controls:5.51%
cases:6.12%
controls:0.95%
—
—
—
—
cases:11.72%
controls:6.80%
cases:20.44%
controls:18.53%
15
120
132
1350
14
81
133
1389
9
14
138
1456
—
—
17
98
128
1344
28
255
109
1121
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
-4.6e-02
6.3e-01
1.8e+00
—
1.5e+00
7.7e-01
1.4e-01
cases:11.56%
controls:12.04%
cases:14.97%
controls:8.57%
cases:11.56%
controls:2.04%
—
—
cases:4.79%
controls:1.16%
cases:18.62%
controls:9.57%
cases:25.55%
controls:22.89%
17
177
130
1293
22
126
125
1344
17
30
130
1440
—
7
17
139
1450
27
138
118
1304
35
315
102
1061
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:0.87%
—
—
—
—
—
—
7
12
130
1364
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
22748-8 [3001308]
-1.5e-02
4.2e-01
1.8e+00
—
—
6.6e-01
1.7e-01
cases:10.20%
controls:10.34%
cases:10.20%
controls:6.94%
cases:5.44%
controls:0.95%
—
—
—
—
cases:14.48%
controls:8.04%
cases:24.82%
controls:21.73%
15
152
132
1318
15
102
132
1368
8
14
139
1456
—
—
21
116
124
1326
34
299
103
1077
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.8e+00
—
—
—
—
—
1.1e+00
cases:6.12%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.96%
9
16
138
1454
—
—
—
—
—
8
27
129
1349
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
14647-2 [3019900]
1.3e-01
5.8e-01
1.7e+00
—
—
7.9e-01
4.1e-01
cases:11.56%
controls:10.27%
cases:10.88%
controls:6.39%
cases:5.44%
controls:1.02%
—
—
—
—
cases:15.17%
controls:7.49%
cases:27.74%
controls:20.35%
17
151
130
1319
16
94
131
1376
8
15
139
1455
—
—
22
108
123
1334
38
280
99
1096
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
1.1e-01
—
-1.0e+50
—
—
1.3e+00
1.7e+00
cases:3.40%
controls:3.06%
—
—
cases:0.00%
controls:0.41%
—
—
—
—
cases:4.83%
controls:1.32%
cases:13.14%
controls:2.69%
5
45
142
1425
—
0
6
147
1464
—
—
7
19
138
1423
18
37
119
1339
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
1.1e+00
—
—
—
—
—
1.7e+00
cases:4.08%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:1.31%
6
20
141
1450
—
—
—
—
—
9
18
128
1358
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-2.2e-01
3.4e-01
1.6e+00
—
1.4e+00
5.9e-01
1.2e-01
cases:8.16%
controls:9.93%
cases:10.88%
controls:8.03%
cases:8.84%
controls:1.84%
—
—
cases:5.48%
controls:1.36%
cases:13.79%
controls:8.11%
cases:21.17%
controls:19.26%
12
146
135
1324
16
118
131
1352
13
27
134
1443
—
8
20
138
1447
20
117
125
1325
29
265
108
1111
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
1.1e+00
1.9e+00
—
—
—
1.8e+00
1.6e+00
cases:4.76%
controls:1.63%
cases:4.08%
controls:0.61%
—
—
—
—
—
—
cases:4.14%
controls:0.69%
cases:10.95%
controls:2.33%
7
24
140
1446
6
9
141
1461
—
—
—
6
10
139
1432
15
32
122
1344
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
2.6e-01
6.8e-01
1.6e+00
—
1.6e+00
6.3e-01
3.4e-01
cases:10.20%
controls:8.03%
cases:12.24%
controls:6.60%
cases:9.52%
controls:2.04%
—
—
cases:4.79%
controls:1.02%
cases:12.41%
controls:7.00%
cases:21.17%
controls:16.06%
15
118
132
1352
18
97
129
1373
14
30
133
1440
—
7
15
139
1452
18
101
127
1341
29
221
108
1155
enalapril and diuretics
C09BA02 [21601804]
C09BA02 [21601804]
1.6e+00
1.5e+00
—
—
—
1.1e+00
1.0e+00
cases:6.12%
controls:1.29%
cases:4.76%
controls:1.16%
—
—
—
—
—
—
cases:3.45%
controls:1.18%
cases:5.11%
controls:1.89%
9
19
138
1451
7
17
140
1453
—
—
—
5
17
140
1425
7
26
130
1350
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:1.45%
—
—
—
—
—
—
9
20
128
1356
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:1.45%
—
—
—
—
—
—
9
20
128
1356
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
1.5e+00
—
—
—
—
1.8e+00
9.2e-01
cases:6.80%
controls:1.56%
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.69%
cases:5.84%
controls:2.40%
10
23
137
1447
—
—
—
—
6
10
139
1432
8
33
129
1343
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.57%
controls:1.53%
—
—
—
—
—
—
9
21
128
1355
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
8.4e-01
1.5e+00
—
—
—
1.4e+00
5.2e-01
cases:8.84%
controls:4.01%
cases:6.80%
controls:1.63%
—
—
—
—
—
—
cases:5.52%
controls:1.39%
cases:9.49%
controls:5.89%
13
59
134
1411
10
24
137
1446
—
—
—
8
20
137
1422
13
81
124
1295
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
1.8e+00
—
—
—
—
1.9e+00
1.4e+00
cases:4.08%
controls:0.68%
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.55%
cases:7.30%
controls:1.82%
6
10
141
1460
—
—
—
—
5
8
140
1434
10
25
127
1351
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
9.8e-01
1.9e+00
—
—
—
2.3e+00
1.4e+00
cases:4.08%
controls:1.56%
cases:3.40%
controls:0.54%
—
—
—
—
—
—
cases:3.45%
controls:0.35%
cases:7.30%
controls:1.82%
6
23
141
1447
5
8
142
1462
—
—
—
5
5
140
1437
10
25
127
1351
Rheumatology
66 [38004491]
66 [38004491]
9.9e-01
1.7e+00
—
—
—
1.3e+00
1.4e+00
cases:3.40%
controls:1.29%
cases:3.40%
controls:0.61%
—
—
—
—
—
—
cases:3.45%
controls:0.97%
cases:10.95%
controls:2.83%
5
19
142
1451
5
9
142
1461
—
—
—
5
14
140
1428
15
39
122
1337
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
1.4e+00
1.1e+00
—
—
—
1.1e+00
4.5e-01
cases:13.61%
controls:3.74%
cases:4.08%
controls:1.36%
—
—
—
—
—
—
cases:5.52%
controls:1.87%
cases:7.30%
controls:4.80%
20
55
127
1415
6
20
141
1450
—
—
—
8
27
137
1415
10
66
127
1310
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
3.1e-01
—
—
—
—
—
1.3e+00
cases:3.40%
controls:2.52%
—
—
—
—
—
—
—
—
—
—
cases:8.76%
controls:2.54%
5
37
142
1433
—
—
—
—
—
12
35
125
1341
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.6e-01
—
—
—
—
1.4e+00
1.3e+00
cases:3.40%
controls:1.97%
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.04%
cases:11.68%
controls:3.56%
5
29
142
1441
—
—
—
—
6
15
139
1427
16
49
121
1327
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
1.4e-01
1.4e-01
1.3e+00
—
8.9e-01
3.9e-01
9.3e-02
cases:17.01%
controls:15.17%
cases:17.01%
controls:15.10%
cases:16.33%
controls:5.17%
—
—
cases:10.27%
controls:4.50%
cases:21.38%
controls:15.53%
cases:30.66%
controls:28.71%
25
223
122
1247
25
222
122
1248
24
76
123
1394
—
15
66
131
1401
31
224
114
1218
42
395
95
981
Pain in joint
M25.5 [45586941]
M25.5 [45586941]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.76%
controls:2.62%
—
—
—
—
—
—
12
36
125
1340
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.49%
controls:3.05%
—
—
—
—
—
—
13
42
124
1334
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
5.9e-01
—
—
—
—
—
1.2e+00
cases:4.08%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
cases:10.22%
controls:3.34%
6
34
141
1436
—
—
—
—
—
14
46
123
1330
Pulmonary Disease
29 [38004472]
29 [38004472]
1.0e-01
4.4e-01
—
—
—
1.0e+00
1.1e+00
cases:7.48%
controls:6.80%
cases:4.76%
controls:3.13%
—
—
—
—
—
—
cases:8.28%
controls:3.19%
cases:18.98%
controls:7.41%
11
100
136
1370
7
46
140
1424
—
—
—
12
46
133
1396
26
102
111
1274
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
4.2e-01
5.5e-01
1.5e+00
—
—
1.1e+00
9.8e-01
cases:7.48%
controls:5.03%
cases:5.44%
controls:3.20%
cases:4.08%
controls:0.95%
—
—
—
—
cases:6.90%
controls:2.50%
cases:16.79%
controls:7.05%
11
74
136
1396
8
47
139
1423
6
14
141
1456
—
—
10
36
135
1406
23
97
114
1279
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
9.8e-01
—
—
—
—
—
8.4e-01
cases:11.56%
controls:4.69%
—
—
—
—
—
—
—
—
—
—
cases:8.03%
controls:3.63%
17
69
130
1401
—
—
—
—
—
11
50
126
1326
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
4.1e-01
1.3e+00
—
—
—
1.1e+00
9.7e-01
cases:4.76%
controls:3.20%
cases:5.44%
controls:1.50%
—
—
—
—
—
—
cases:4.83%
controls:1.73%
cases:14.60%
controls:6.10%
7
47
140
1423
8
22
139
1448
—
—
—
7
25
138
1417
20
84
117
1292
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
1.0e+00
5.9e-01
2.0e+00
—
—
1.2e+00
9.6e-01
cases:8.16%
controls:3.13%
cases:3.40%
controls:1.90%
cases:3.40%
controls:0.48%
—
—
—
—
cases:5.52%
controls:1.80%
cases:13.14%
controls:5.45%
12
46
135
1424
5
28
142
1442
5
7
142
1463
—
—
8
26
137
1416
18
75
119
1301
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.9e+00
-1.0e+00
—
—
—
—
2.9e+00
cases:5.44%
controls:27.96%
cases:3.40%
controls:8.98%
—
—
—
—
—
—
—
—
cases:12.41%
controls:0.80%
8
411
139
1059
5
132
142
1338
—
—
—
—
17
11
120
1365
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
47210-0 [3048773]
8.4e-02
6.7e-01
1.6e+00
—
—
9.4e-01
1.7e-01
cases:10.20%
controls:9.46%
cases:9.52%
controls:5.10%
cases:4.08%
controls:0.82%
—
—
—
—
cases:13.79%
controls:5.89%
cases:21.17%
controls:18.46%
15
139
132
1331
14
75
133
1395
6
12
141
1458
—
—
20
85
125
1357
29
254
108
1122
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
1.8e-01
1.3e+00
—
—
—
1.5e+00
9.3e-01
cases:3.40%
controls:2.86%
cases:4.76%
controls:1.36%
—
—
—
—
—
—
cases:6.21%
controls:1.53%
cases:14.60%
controls:6.32%
5
42
142
1428
7
20
140
1450
—
—
—
9
22
136
1420
20
87
117
1289
amoxicillin; oral, parenteral
J01CA04 [21602823]
J01CA04 [21602823]
5.7e-01
9.7e-01
—
—
—
5.9e-01
7.6e-01
cases:27.21%
controls:17.48%
cases:10.88%
controls:4.42%
—
—
—
—
—
—
cases:10.34%
controls:6.03%
cases:32.85%
controls:18.60%
40
257
107
1213
16
65
131
1405
—
—
—
15
87
130
1355
45
256
92
1120
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
2.2e-01
1.9e-01
—
—
—
7.6e-01
7.0e-01
cases:19.05%
controls:15.92%
cases:10.88%
controls:9.18%
—
—
—
—
—
—
cases:17.93%
controls:9.29%
cases:40.88%
controls:25.51%
28
234
119
1236
16
135
131
1335
—
—
—
26
134
119
1308
56
351
81
1025
Eye discharge
F03 [2002000401]
F03 [2002000401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
30934-4 [3011960]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
0
9
147
1461
—
—
—
—
—
0
10
137
1366
Pure hypercholesterolaemia
E78.01 [2000501514]
E78.01 [2000501514]
9.9e-01
1.7e+00
—
—
—
—
7.1e-01
cases:3.40%
controls:1.29%
cases:4.08%
controls:0.75%
—
—
—
—
—
—
—
—
cases:6.57%
controls:3.34%
5
19
142
1451
6
11
141
1459
—
—
—
—
9
46
128
1330
diclofenac, combinations; oral
M01AB55 [21603959]
M01AB55 [21603959]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
Fracture of lateral malleolus
S82.6 [45569819]
S82.6 [45569819]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
E11.7 [45561950]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
Retinal detachment with retinal break
H33.0 [45547857]
H33.0 [45547857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
codeine and ibuprofen
N02AJ08 [1123631]
N02AJ08 [1123631]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
Parabulbar anesthesia
WX140 [2001310772]
WX140 [2001310772]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
misoprostol; oral, vaginal
G02AD06 [21602443]
G02AD06 [21602443]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
brompheniramine, combinations
R06AB51 [21603466]
R06AB51 [21603466]
3.2e-01
—
—
—
—
—
—
cases:4.08%
controls:2.99%
—
—
—
—
—
—
—
—
—
—
—
—
6
44
141
1426
—
—
—
—
—
—
Surveillance of contraceptive drugs
Z30.4 [45547299]
Z30.4 [45547299]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
137
1369
solifenacin; oral
G04BD08 [21602641]
G04BD08 [21602641]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
14
147
1456
0
5
147
1465
—
—
—
—
0
11
137
1365
Mouth breathing
R06.5 [45573006]
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
147
1457
—
—
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
AA1BG [2001300112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
Malignant tumour
130 [2001600128]
130 [2001600128]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
chlorprothixene; oral, parenteral
N05AF03 [21604533]
N05AF03 [21604533]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Application of soft bandage
SPAT1211 [2001700312]
SPAT1211 [2001700312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Impingement syndrome of shoulder
M75.4 [45553266]
M75.4 [45553266]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.51%
—
—
—
—
—
0
6
145
1436
0
7
137
1369
rosuvastatin; oral
C10AA07 [21601862]
C10AA07 [21601862]
8.3e-01
5.0e-01
—
—
—
1.1e+00
2.8e-01
cases:5.44%
controls:2.45%
cases:4.08%
controls:2.52%
—
—
—
—
—
—
cases:6.90%
controls:2.43%
cases:8.03%
controls:6.18%
8
36
139
1434
6
37
141
1433
—
—
—
10
35
135
1407
11
85
126
1291
Medical examin/health eval partial
-31 [2002000102]
-31 [2002000102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
7.9e-01
—
—
—
—
1.7e+00
6.8e-01
cases:3.40%
controls:1.56%
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.62%
cases:5.84%
controls:3.05%
5
23
142
1447
—
—
—
—
5
9
140
1433
8
42
129
1334
Rehabilitation Hospital
283X00000X [38004285]
283X00000X [38004285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
Complicated extraction of tooth
EBA05 [2001301924]
EBA05 [2001301924]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
9
145
1433
—
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:1.67%
—
—
—
—
—
—
7
23
130
1353
Cervicocranial syndrome
M53.0 [45562750]
M53.0 [45562750]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
6
147
1464
—
—
—
—
—
0
7
137
1369
ferrous glycine sulfate; oral
B03AA01 [21601080]
B03AA01 [21601080]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
Pain in limb
M79.6 [45587063]
M79.6 [45587063]
9.8e-01
—
—
—
—
—
5.2e-01
cases:5.44%
controls:2.11%
—
—
—
—
—
—
—
—
—
—
cases:8.03%
controls:4.94%
8
31
139
1439
—
—
—
—
—
11
68
126
1308
hydroxychloroquine; oral
P01BA02 [21604889]
P01BA02 [21604889]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:0.87%
—
—
—
—
—
—
5
12
132
1364
Spirometry study
18759-1 [3000492]
18759-1 [3000492]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
0
15
147
1455
—
—
—
—
—
0
13
137
1363
Balloon angioplasty and metallic stent
AN3 [2000200165]
AN3 [2000200165]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
J45.9 [45562456]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:1.96%
—
—
—
—
—
—
6
27
131
1349
Counselling, unspecified
Z71.9 [45561648]
Z71.9 [45561648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
10
137
1366
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
TNX10 [2001308560]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
R10.3 [45534426]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
21
147
1449
—
—
—
—
—
—
alendronic acid; oral
M05BA04 [21604152]
M05BA04 [21604152]
1.5e+00
—
—
—
—
—
1.2e+00
cases:3.40%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:1.38%
5
11
142
1459
—
—
—
—
—
6
19
131
1357
PEF monitoring instruction
SPAT1058 [2001700159]
SPAT1058 [2001700159]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
2714-4 [3014007]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1459
—
—
—
—
—
—
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
4.3e-01
1.0e+00
—
—
—
—
6.8e-01
cases:5.44%
controls:3.61%
cases:4.08%
controls:1.50%
—
—
—
—
—
—
—
—
cases:8.76%
controls:4.65%
8
53
139
1417
6
22
141
1448
—
—
—
—
12
64
125
1312
insulin aspart; parenteral
A10AB05 [21600719]
A10AB05 [21600719]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
J01AA02 [21602800]
-1.7e-01
4.9e-01
—
—
—
3.1e-01
2.0e-01
cases:14.97%
controls:17.21%
cases:9.52%
controls:6.05%
—
—
—
—
—
—
cases:6.90%
controls:5.13%
cases:19.71%
controls:16.79%
22
253
125
1217
14
89
133
1381
—
—
—
10
74
135
1368
27
231
110
1145
Otitis externa
H60 [45581713]
H60 [45581713]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
quetiapine; oral
N05AH04 [21604544]
N05AH04 [21604544]
—
9.9e-01
-1.0e+50
—
—
—
7.2e-01
—
—
cases:3.40%
controls:1.29%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:4.38%
controls:2.18%
—
5
19
142
1451
0
6
147
1464
—
—
—
6
30
131
1346
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
0
18
137
1358
ketoprofen, combinations
M01AE53 [21603985]
M01AE53 [21603985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
piroxicam; ointment
M02AA07 [21604043]
M02AA07 [21604043]
2.2e-01
—
—
—
—
-1.0e+50
2.6e-01
cases:5.44%
controls:4.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:4.38%
controls:3.42%
8
65
139
1405
—
—
—
—
0
13
145
1429
6
47
131
1329
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.30%
controls:2.03%
—
—
—
—
—
—
10
28
127
1348
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
14731-4 [3019309]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
9
145
1433
—
Demanding periodontal treatment
SDA04 [2001310329]
SDA04 [2001310329]
—
-1.0e+50
—
—
—
—
4.9e-01
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:5.11%
controls:3.20%
—
0
10
147
1460
—
—
—
—
7
44
130
1332
Hospital outpatient
ZY010 [2001311599]
ZY010 [2001311599]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
Bacteria [#/volume] in Urine by Culture
100906-7 [1761482]
100906-7 [1761482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
137
1367
Counselling related to known health issue
SPAT1310 [2001700411]
SPAT1310 [2001700411]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1459
—
—
—
—
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
147
1459
—
—
—
—
—
—
timolol
S01ED01 [21603699]
S01ED01 [21603699]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.88%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
0
13
147
1457
0
11
147
1459
—
—
—
0
12
145
1430
—
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
8.6e-02
—
-1.0e+50
—
-1.0e+50
—
6.0e-01
cases:3.40%
controls:3.13%
—
—
cases:0.00%
controls:0.54%
—
—
cases:0.00%
controls:0.61%
—
—
cases:7.30%
controls:4.14%
5
46
142
1424
—
0
8
147
1462
—
0
9
146
1458
—
10
57
127
1319
tiotropium bromide; inhalant
R03BB04 [21603296]
R03BB04 [21603296]
—
—
—
—
—
—
9.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:1.74%
—
—
—
—
—
—
6
24
131
1352
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
E10.9 [45581351]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
cases:0.00%
controls:2.18%
—
—
—
—
—
0
18
145
1424
0
30
137
1346
chlorhexidine, combinations
D08AC52 [21602208]
D08AC52 [21602208]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1437
—
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
Z00.4 [45605094]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
Dizziness and giddiness
R42 [45568132]
R42 [45568132]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:2.03%
—
—
—
—
—
—
5
28
132
1348
General health counselling
SPAT1312 [2001700413]
SPAT1312 [2001700413]
—
—
—
—
—
—
2.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:4.51%
—
—
—
—
—
—
8
62
129
1314
ciclesonide; inhalant
R03BA08 [21603291]
R03BA08 [21603291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
4.0e-01
—
—
—
—
—
5.6e-01
cases:3.40%
controls:2.31%
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:2.11%
5
34
142
1436
—
—
—
—
—
5
29
132
1347
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
C01DA08 [21600321]
6.3e-01
—
—
—
—
—
9.6e-01
cases:4.76%
controls:2.59%
—
—
—
—
—
—
—
—
—
—
cases:8.76%
controls:3.56%
7
38
140
1432
—
—
—
—
—
12
49
125
1327
Amniocentesis
MAA00 [2001306845]
MAA00 [2001306845]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Speech audiometry
252592009 [4091138]
252592009 [4091138]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Syncope and collapse
R55 [45568141]
R55 [45568141]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
147
1461
—
—
—
—
—
—
Blepharitis
H01.0 [45533180]
H01.0 [45533180]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
137
1369
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
2.3e-01
8.6e-01
—
—
—
8.3e-01
2.3e-01
cases:7.48%
controls:6.05%
cases:4.08%
controls:1.77%
—
—
—
—
—
—
cases:3.45%
controls:1.53%
cases:6.57%
controls:5.31%
11
89
136
1381
6
26
141
1444
—
—
—
5
22
140
1420
9
73
128
1303
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.84%
controls:1.53%
—
—
—
—
—
—
8
21
129
1355
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
—
—
—
—
—
—
2.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:3.34%
—
—
—
—
—
—
6
46
131
1330
Allergic rhinitis, unspecified
J30.4 [45548110]
J30.4 [45548110]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Opening and preparing the root canals, complicated
SGA03 [2001310381]
SGA03 [2001310381]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
0
5
147
1465
—
—
—
—
—
0
14
137
1362
Functional diarrhoea
K59.1 [45543327]
K59.1 [45543327]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
5
147
1465
—
—
—
—
—
0
5
137
1371
Gestational [pregnancy-induced] hypertension
O13 [45539091]
O13 [45539091]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
apixaban; oral
B01AF02 [43534762]
B01AF02 [43534762]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
0
5
147
1465
—
—
—
—
0
14
137
1362
Sprain and strain of other and unspecified parts of knee
S83.6 [45579536]
S83.6 [45579536]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1437
—
Striking against or struck by other object(s)
W22 [45756260]
W22 [45756260]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
12
137
1364
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
Z03.89 [2000503757]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
9
137
1367
Other medical or dental certificate
WZA90 [2001310883]
WZA90 [2001310883]
-1.0e+50
—
—
—
—
-1.0e+50
1.1e+00
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:5.11%
controls:1.82%
0
24
147
1446
—
—
—
—
0
7
145
1435
7
25
130
1351
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:0.73%
—
—
—
—
—
—
5
10
132
1366
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
147
1452
—
—
—
—
—
—
clindamycin, combinations
D10AF51 [21602309]
D10AF51 [21602309]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Biopsy of kidney with ultrasound guidance
KA3AT [2001305778]
KA3AT [2001305778]
1.0e+50
1.0e+50
1.0e+50
—
—
—
1.0e+50
cases:4.08%
controls:0.00%
cases:4.08%
controls:0.00%
cases:5.44%
controls:0.00%
—
—
—
—
—
—
cases:5.11%
controls:0.00%
6
0
141
1470
6
0
141
1470
8
0
139
1470
—
—
—
7
0
130
1376
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
70204-3 [42868678]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
0
19
137
1357
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
M01AE03 [21603969]
3.7e-01
—
—
—
—
—
-3.6e-01
cases:8.84%
controls:6.26%
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:5.16%
13
92
134
1378
—
—
—
—
—
5
71
132
1305
Fear of hypertension
K25 [2002000553]
K25 [2002000553]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
137
1369
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
3.2e-01
1.3e-01
-1.0e+50
—
-1.0e+50
—
-1.5e-01
cases:11.56%
controls:8.71%
cases:4.76%
controls:4.22%
cases:0.00%
controls:0.41%
—
—
cases:0.00%
controls:0.55%
—
—
cases:6.57%
controls:7.56%
17
128
130
1342
7
62
140
1408
0
6
147
1464
—
0
8
146
1459
—
9
104
128
1272
Maternal care for excessive fetal growth
O36.6 [45543983]
O36.6 [45543983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Systolic blood pressure
8480-6 [3004249]
8480-6 [3004249]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:0.00%
—
—
—
—
—
—
5
0
132
1376
melatonin; oral
N05CH01 [21604659]
N05CH01 [21604659]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
0
8
147
1462
—
—
—
0
10
145
1432
—
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
—
—
—
—
-1.0e+50
—
9.4e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:7.30%
controls:2.98%
—
—
—
—
0
5
146
1462
—
10
41
127
1335
Laparoscopic cholecystectomy
JKA21 [2001305294]
JKA21 [2001305294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
12
137
1364
Asthma
R96 [2002000961]
R96 [2002000961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
14
137
1362
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
19230-2 [3014218]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
Protein [Mass] in Urine collected for unspecified duration
32551-4 [3017817]
32551-4 [3017817]
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:3.40%
controls:0.00%
cases:3.40%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
142
1470
5
0
142
1470
—
—
—
—
Abdominal pain epigastric
D02 [2002000301]
D02 [2002000301]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
8
137
1368
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
OMOP4821991 [45756751]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
9
147
1461
—
—
—
—
0
6
145
1436
—
Cough
R05 [2002000886]
R05 [2002000886]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
ambroxol; oral
R05CB06 [21603385]
R05CB06 [21603385]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.22%
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
0
18
147
1452
0
5
147
1465
—
—
—
—
—
amphotericin B; oral
A07AA07 [21600609]
A07AA07 [21600609]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
0
6
147
1464
—
—
—
—
—
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
M05BB03 [21604160]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Cervicalgia
M54.2 [45591867]
M54.2 [45591867]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Metabolic syndrome
E66.00 [2000501500]
E66.00 [2000501500]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
6
145
1436
—
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
10501-5 [3009214]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
mianserin; oral
N06AX03 [21604732]
N06AX03 [21604732]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
6.2e-01
4.9e-01
—
—
—
1.2e+00
6.6e-01
cases:9.52%
controls:5.37%
cases:3.40%
controls:2.11%
—
—
—
—
—
—
cases:6.90%
controls:2.29%
cases:12.41%
controls:6.83%
14
79
133
1391
5
31
142
1439
—
—
—
10
33
135
1409
17
94
120
1282
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
11
137
1365
celecoxib; oral
M01AH01 [21603992]
M01AH01 [21603992]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
9
145
1433
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
M01AC06 [21603965]
2.0e-01
—
-1.0e+50
—
—
—
—
cases:4.76%
controls:3.95%
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
7
58
140
1412
—
0
7
147
1463
—
—
—
—
Other dorsalgia
M54.8 [45538790]
M54.8 [45538790]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
lactulose; oral
A06AD11 [21600571]
A06AD11 [21600571]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.03%
—
—
—
—
—
—
0
28
137
1348
chlorhexidine
S02AA09 [21605155]
S02AA09 [21605155]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1437
—
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
7.1e-01
3.9e-01
—
—
—
—
1.6e-01
cases:14.97%
controls:7.96%
cases:4.08%
controls:2.79%
—
—
—
—
—
—
—
—
cases:8.76%
controls:7.56%
22
117
125
1353
6
41
141
1429
—
—
—
—
12
104
125
1272
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
6.1e-01
—
—
—
—
5.5e-01
4.3e-01
cases:8.16%
controls:4.63%
—
—
—
—
—
—
—
—
cases:3.45%
controls:2.01%
cases:8.76%
controls:5.89%
12
68
135
1402
—
—
—
—
5
29
140
1413
12
81
125
1295
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
J44.0 [45601131]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
7
137
1369
Functional dyspepsia
K30 [45591584]
K30 [45591584]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
10
137
1366
Deposits [accretions] on teeth betel
K03.65 [2000502690]
K03.65 [2000502690]
—
-1.0e+50
—
—
—
—
9.4e-01
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.65%
controls:1.45%
—
0
7
147
1463
—
—
—
—
5
20
132
1356
formoterol; inhalant
R03AC13 [21603267]
R03AC13 [21603267]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
0
10
147
1460
0
8
147
1462
—
—
—
0
5
145
1437
—
Chronic atrial fibrillation
I48.2 [45591467]
I48.2 [45591467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
celecoxib
L01XX33 [21603805]
L01XX33 [21603805]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
9
145
1433
—
Consultation of another employee
SPAT1260 [2001700361]
SPAT1260 [2001700361]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.50%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
0
22
147
1448
—
—
—
—
0
7
145
1435
—
Excessive ear wax
H81 [2002000536]
H81 [2002000536]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
8
145
1434
—
chlorhexidine
D09AA12 [21602275]
D09AA12 [21602275]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1437
—
Pneumonia
R81 [2002000949]
R81 [2002000949]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Other primary gonarthrosis
M17.1 [45596493]
M17.1 [45596493]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
0
13
147
1457
—
—
—
—
—
tolterodine; oral
G04BD07 [21602640]
G04BD07 [21602640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
O24.0 [45558213]
O24.0 [45558213]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
5
147
1465
—
—
—
—
—
0
8
137
1368
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
5.5e-01
1.0e+00
—
—
—
—
4.0e-01
cases:5.44%
controls:3.20%
cases:3.40%
controls:1.22%
—
—
—
—
—
—
—
—
cases:6.57%
controls:4.51%
8
47
139
1423
5
18
142
1452
—
—
—
—
9
62
128
1314
tolfenamic acid; oral, rectal
M01AG02 [21603988]
M01AG02 [21603988]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
—
—
—
—
—
—
5.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.11%
controls:2.91%
—
—
—
—
—
—
7
40
130
1336
Patch test
41778007 [4218642]
41778007 [4218642]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
Hypertrophy of breast
N62 [45577538]
N62 [45577538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
147
1465
—
—
—
—
—
—
Gas panel - Arterial blood
24336-0 [3019060]
24336-0 [3019060]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
147
1463
—
—
—
—
—
—
Hyperplasia of prostate
N40 [45563015]
N40 [45563015]
8.9e-01
—
—
—
—
—
—
cases:3.40%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
142
1449
—
—
—
—
—
—
chloramphenicol
S02AA01 [21605147]
S02AA01 [21605147]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
6
137
1370
long-acting sulfonamides - combinations
J01ED20 [21602959]
J01ED20 [21602959]
4.2e-01
—
—
—
—
—
—
cases:4.08%
controls:2.72%
—
—
—
—
—
—
—
—
—
—
—
—
6
40
141
1430
—
—
—
—
—
—
dutasteride; oral
G04CB02 [21602676]
G04CB02 [21602676]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:1.24%
—
0
5
147
1465
—
—
—
0
7
145
1435
0
17
137
1359
econazole
D01AC03 [21601922]
D01AC03 [21601922]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
5
145
1437
—
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
Y83 [45552036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
5
137
1371
Genetic counselling
Z31.5 [45590715]
Z31.5 [45590715]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
147
1462
—
—
—
—
—
—
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
1.9e+00
—
—
—
—
—
1.3e+00
cases:3.40%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.65%
controls:1.02%
5
8
142
1462
—
—
—
—
—
5
14
132
1362
simvastatin; oral
C10AA01 [21601856]
C10AA01 [21601856]
2.3e-01
3.7e-01
6.5e-01
—
9.6e-01
7.0e-01
4.0e-01
cases:13.61%
controls:11.09%
cases:11.56%
controls:8.30%
cases:4.08%
controls:2.18%
—
—
cases:6.16%
controls:2.45%
cases:16.55%
controls:8.95%
cases:18.98%
controls:13.59%
20
163
127
1307
17
122
130
1348
6
32
141
1438
—
9
36
137
1431
24
129
121
1313
26
187
111
1189
Appendicectomy
6421 [2000100987]
6421 [2000100987]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
147
1464
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
113
448
7.05
27.90
17.5
3.8
55.60
6.99
mg/mmol
8.28
105
282
114
456
7.12
27.85
14.6
3.1
7.04
8.26
mmol/l
2.53
109
376
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
31
33
11.56
27.15
6.5
2.2
0.26
0.36
iu/ml
0.76
18
19
71
193
6.06
26.72
10.4
2.1
27.86
23.13
%
1.72
71
182
36
49
9.33
26.26
2.2
3.2
58.32
31.17
mg/l
2.63
28
41
36
49
9.33
26.26
2.2
3.2
62.91
25.98
mg/l
1.74
28
41
35
46
9.60
26.24
2.1
2.6
1.14
1.28
ratio
0.49
22
26
42
75
7.37
24.13
15.1
2.7
22.84
24.40
mmol/l
2.57
42
75
56
136
5.96
23.51
14.9
2.9
5.85
5.62
kpa
0.95
56
131
98
391
5.29
22.53
11.4
3.0
0.17
0.38
e6/l
2.12
93
287
43
86
6.59
22.01
11.8
8.2
23.34
24.57
mmol/l
1.15
43
86
48
107
6.11
21.96
7.4
3.1
34.59
65.91
ml/min/173m2
7.90
32
47
30
19
19.38
19.81
11.7
3.5
11.84
12.47
pmol/l
0.05
30
19
46
109
5.63
19.51
6.7
2.8
62.20
66.94
g/l
2.80
46
102
27
13
24.95
19.45
8.9
4.7
2143.78
448.23
mg
4.70
27
13
118
593
5.53
19.12
28.6
7.2
1.22
1.21
mmol/l
0.78
118
546
124
652
6.04
18.88
36.1
7.9
1.21
1.21
mmol/l
0.15
117
557
44
117
4.90
16.08
9.8
2.7
5.98
4.39
kpa
2.59
44
112
12
0
+∞
12.67
10.3
0.0
5.37
—
mmol/l
—
12
0
31
77
4.81
12.09
7.3
2.5
0.63
0.64
%
0.06
31
77
31
77
4.81
12.09
8.1
2.5
0.95
1.26
%
1.21
31
77
31
78
4.74
11.90
6.7
2.4
-0.16
2.09
mmol/l
1.65
14
62
56
218
3.49
11.70
10.0
3.0
1.15
2.06
e6/l
0.58
41
109
11
0
+∞
11.60
4.6
0.0
—
—
—
0
0
115
694
3.76
11.57
10.5
3.9
0.03
0.00
estimate
0.49
39
148
116
705
3.78
11.52
10.5
4.0
0.00
0.00
estimate
-0.00
39
148
59
242
3.36
11.28
7.9
2.8
1.02
0.94
e6/l
0.05
44
130
116
712
3.71
11.18
10.6
4.0
0.00
0.03
estimate
0.50
37
140
45
170
3.35
9.65
6.0
4.3
245.62
242.41
u/l
0.05
45
160
20
43
5.21
9.12
1.8
1.5
—
0.07
—
0
11
18
21
9.57
9.10
2.4
1.1
353.36
244.33
u/ml
—
11
9
19
40
5.29
8.86
2.1
1.2
—
—
—
0
0
25
68
4.21
8.59
4.7
1.5
9.49
10.03
iu/ml
—
9
19
49
213
2.93
8.13
17.4
7.6
104.27
104.33
mmol/l
0.03
49
213
39
150
3.16
8.00
6.7
3.2
—
—
—
0
0
114
771
2.95
7.80
16.6
10.8
3.86
4.25
e9/l
1.18
103
680
19
46
4.58
7.52
3.3
2.3
9.81
10.50
g/l
0.15
19
41
10
5
21.26
7.23
1.1
1.0
—
—
—
0
0
37
148
2.99
7.03
2.4
2.1
322.11
384.19
nmol/l
1.06
37
140
13
16
8.77
6.48
1.7
1.1
—
—
—
0
0
11
12
9.78
5.89
1.2
1.1
—
—
—
0
0
38
171
2.63
5.72
2.1
2.0
—
—
—
0
0
14
25
6.06
5.53
9.3
2.8
4.89
5.02
kpa
0.25
14
25
67
395
2.25
5.51
12.2
4.1
0.00
0.00
estimate
-0.00
27
136
38
175
2.57
5.44
2.2
1.9
—
—
—
0
0
27
104
2.94
5.42
20.8
4.0
1.21
1.22
mmol/l
0.26
27
92
56
310
2.28
5.33
4.1
2.5
—
—
—
0
0
13
27
5.16
4.62
1.2
1.1
—
—
—
0
0
15
37
4.38
4.55
1.3
1.2
—
—
—
0
0
14
35
4.30
4.23
2.4
1.5
—
—
—
0
0
24
99
2.69
4.23
2.0
1.5
—
—
—
0
0
15
47
3.43
4.18
5.4
1.8
89.27
88.28
%
0.05
15
47
80
549
1.97
4.07
10.8
3.9
0.03
0.00
estimate
0.49
33
132
10
19
5.55
3.90
2.3
1.4
—
—
—
0
0
13
34
4.08
3.80
2.2
1.8
—
—
—
0
0
14
40
3.75
3.72
8.4
1.9
246.86
216.72
%
0.34
14
40
34
175
2.22
3.72
13.4
11.2
5.03
5.05
kpa
0.06
34
170
34
175
2.22
3.72
13.4
11.2
14.83
12.54
kpa
0.66
34
170
13
35
3.96
3.69
4.3
2.6
0.00
0.00
g/l
-0.00
13
35
41
230
2.07
3.61
2.4
2.0
—
—
—
0
0
9
19
4.97
3.29
2.3
1.4
—
—
—
0
0
6
7
8.86
3.29
2.2
1.4
—
—
—
0
0
10
26
4.04
3.04
2.3
1.5
—
—
—
0
0
10
26
4.04
3.04
1.6
1.3
—
—
—
0
0
60
405
1.80
2.98
10.3
3.2
0.61
0.00
estimate
0.49
33
123
15
59
2.71
2.89
1.9
2.3
50.87
42.25
u/l
0.32
15
50
82
614
1.73
2.79
4.2
3.0
—
—
estimate
—
0
0
5
6
8.56
2.77
2.4
1.2
—
—
—
0
0
43
269
1.84
2.70
3.5
3.4
104.29
187.40
ng/l
0.32
31
210
5
7
7.34
2.57
2.4
1.3
—
—
—
0
0
75
563
1.66
2.42
2.4
2.1
106.40
95.25
pmol/l
1.14
40
283
9
28
3.35
2.35
2.0
1.6
—
—
—
0
0
14
60
2.47
2.29
1.4
2.1
0.40
1.31
ug/l
1.17
14
53
6
13
4.76
2.29
2.5
1.6
—
—
—
0
0
40
259
1.74
2.21
5.6
2.8
2.50
2.45
mmol/l
0.97
32
226
11
42
2.74
2.19
2.3
1.7
—
—
—
0
0
11
42
2.74
2.19
1.3
1.3
—
36.97
—
0
6
15
70
2.27
2.06
1.5
1.8
—
—
—
0
0
8
27
3.07
1.96
1.6
1.4
—
—
—
0
0
8
27
3.07
1.96
1.6
1.4
—
—
—
0
0
5
11
4.66
1.95
3.2
1.3
—
—
—
0
0
7
23
3.14
1.82
2.3
1.7
—
—
—
0
0
8
29
2.85
1.82
2.1
1.7
—
—
—
0
0
9
36
2.59
1.77
1.9
1.3
—
—
—
0
0
9
36
2.59
1.77
2.0
1.6
—
—
—
0
0
5
13
3.94
1.73
1.4
1.1
—
—
—
0
0
5
13
3.94
1.73
1.2
1.1
—
—
—
0
0
22
128
1.84
1.72
1.3
2.9
0.26
0.22
g/l
1.05
22
117
10
42
2.48
1.65
2.4
1.7
—
—
—
0
0
43
310
1.54
1.52
10.1
4.3
1.02
1.02
kg/l
0.37
31
198
10
45
2.31
1.50
1.3
1.2
—
—
—
0
0
6
22
2.80
1.45
1.5
1.3
—
—
—
0
0
137
1270
1.85
1.38
49.0
16.9
20.17
24.51
mg/l
1.21
127
1050
109
962
1.48
1.33
4.5
4.2
14.73
14.92
pmol/l
0.31
104
866
10
48
2.16
1.31
2.6
2.6
—
—
—
0
0
14
77
1.90
1.30
1.4
1.2
—
—
—
0
0
139
1299
1.88
1.29
59.9
19.6
139.58
139.71
mmol/l
0.24
139
1273
139
1301
1.86
1.25
64.4
19.7
4.17
3.99
mmol/l
6.99
139
1271
5
20
2.55
1.16
1.0
1.1
—
—
—
0
0
45
349
1.41
1.09
2.7
3.2
0.99
0.78
ug/l
0.57
37
214
13
75
1.80
1.06
2.5
3.5
4.27
4.40
pmol/l
0.26
13
66
6
30
2.04
0.88
1.2
1.8
—
—
—
0
0
8
46
1.78
0.84
2.1
2.1
—
—
—
0
0
37
290
1.37
0.84
1.3
1.3
0.63
0.93
u/ml
1.19
16
78
56
468
1.31
0.83
3.3
4.6
30.16
21.99
%
2.06
28
219
9
54
1.71
0.76
2.0
2.0
—
—
—
0
0
7
40
1.79
0.72
2.3
1.8
—
—
—
0
0
5
30
1.69
0.62
2.4
1.4
—
—
—
0
0
8
52
1.57
0.60
1.0
1.5
344.38
271.01
mu/l
—
8
47
65
574
1.23
0.58
2.9
2.0
1.77
1.38
mmol/l
0.49
57
470
62
549
1.22
0.53
5.7
3.9
55.80
40.50
ng/l
0.66
48
409
139
1347
1.40
0.46
58.7
21.6
170.83
78.07
umol/l
8.09
139
1334
7
51
1.39
0.44
1.3
1.2
—
—
—
0
0
5
31
1.63
0.43
1.2
1.3
—
—
—
0
0
19
150
1.31
0.42
1.2
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
5.2
—
116.78
—
0
15
0
16
0.00
0.41
0.0
1.1
—
1.35
—
0
6
0
17
0.00
0.41
0.0
1.5
—
1.01
—
0
9
0
17
0.00
0.41
0.0
1.5
—
1.25
—
0
9
0
17
0.00
0.41
0.0
1.5
—
0.97
—
0
9
0
17
0.00
0.41
0.0
4.1
—
16.56
—
0
9
5
34
1.49
0.40
1.2
1.1
—
—
—
0
0
5
34
1.49
0.40
1.2
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
55.13
—
0
12
0
19
0.00
0.39
0.0
1.2
—
1.32
—
0
5
16
125
1.31
0.39
1.3
2.0
—
—
—
0
0
17
135
1.29
0.37
1.4
2.2
—
—
—
0
0
81
765
1.13
0.27
3.4
3.1
—
—
—
0
0
19
161
1.21
0.25
14.1
7.6
—
—
—
0
0
25
218
1.18
0.25
1.3
1.4
3.23
6.82
u/ml
—
10
83
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
198.75
—
0
10
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
0.92
—
0
13
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
7.58
—
0
6
0
14
0.00
0.20
0.0
1.5
—
189.54
—
0
14
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
139
1377
1.12
0.08
71.4
25.2
239.33
244.17
e9/l
0.44
139
1355
139
1378
1.11
0.07
73.8
25.7
38.78
40.78
%
4.55
139
1366
139
1378
1.11
0.07
71.2
25.1
93.06
91.27
fl
4.81
139
1367
139
1379
1.10
0.06
72.0
25.3
127.46
136.84
g/l
7.63
139
1366
24
251
0.95
0.04
1.3
1.3
23.73
30.81
iu/ml
—
7
79
22
230
0.95
0.04
1.3
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
29.83
—
0
6
0
6
0.00
-0.00
0.0
4.5
—
10.05
—
0
6
12
120
1.00
-0.00
1.3
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.5
—
4.61
—
0
6
6
69
0.86
-0.00
1.2
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
6.87
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
7.41
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
48.38
—
0
8
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: N14_MEMBRANOUS_NEPHROPATHY – Membranous nephropathy
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).